We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+4.15%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$12.2B
AUM Growth
+$1.52B
Cap. Flow
+$1.17B
Cap. Flow %
9.66%
Top 10 Hldgs %
19.97%
Holding
2,123
New
434
Increased
455
Reduced
367
Closed
827

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$197M
2
BABA icon
Alibaba
BABA
+$190M
3
AMZN icon
Amazon
AMZN
+$161M
4
GDDY icon
GoDaddy
GDDY
+$135M
5
DIS icon
Walt Disney
DIS
+$132M

Sector Composition

Rank Sector Weight
1 Healthcare 24.88%
2 Consumer Discretionary 23.99%
3 Technology 11.1%
4 Financials 8.14%
5 Industrials 7.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MGP
2001
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
-5,279
Closed -$170K
HMHC
2002
DELISTED
Houghton Mifflin Harcourt Company
HMHC
-258,488
Closed -$1.88M
FLOW
2003
DELISTED
SPX FLOW, Inc.
FLOW
-101,090
Closed -$3.23M
SUNS
2004
DELISTED
SLR Senior Investment Corp. Common Stock
SUNS
-2,441
Closed -$42K
CSLT
2005
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
-299,705
Closed -$1.12M
MRLN
2006
DELISTED
Marlin Business Services Corp
MRLN
-11,620
Closed -$250K
DRNA
2007
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
-202,213
Closed -$2.96M
ZIXI
2008
DELISTED
Zix Corporation
ZIXI
-96,638
Closed -$665K
KSU
2009
DELISTED
Kansas City Southern
KSU
-202,971
Closed -$23.5M
CVA
2010
DELISTED
Covanta Holding Corporation
CVA
-52,039
Closed -$901K
XLRN
2011
DELISTED
Acceleron Pharma
XLRN
-208,333
Closed -$9.7M
TRIL
2012
DELISTED
Trillium Therapeutics Inc.
TRIL
-110,282
Closed -$73K
XOG
2013
DELISTED
Extraction Oil & Gas, Inc. Common Stock
XOG
-4,165,682
Closed -$17.6M
CSOD
2014
DELISTED
Cornerstone OnDemand, Inc.
CSOD
-15,224
Closed -$834K
SBBP
2015
DELISTED
Strongbridge Biopharma plc.
SBBP
-4,529
Closed -$23K
ARD
2016
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
-140,447
Closed -$1.83M
BOCH
2017
DELISTED
Bank of Commerce Holdings (CA)
BOCH
-24,639
Closed -$260K
ALTA
2018
DELISTED
Altabancorp
ALTA
-3,046
Closed -$80K
KIN
2019
DELISTED
Kindred Biosciences, Inc.
KIN
-5,760
Closed -$53K
MXIM
2020
DELISTED
Maxim Integrated Products
MXIM
-23,425
Closed -$1.25M
TLND
2021
DELISTED
Talend S.A. American Depositary Shares
TLND
-5,877
Closed -$297K
BPYU
2022
DELISTED
Brookfield Property REIT Inc. Class A Common Stock
BPYU
-445,561
Closed -$9.13M
BPY
2023
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
-631,501
Closed -$13M
STAY
2024
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
-500,424
Closed -$8.98M
LEAF
2025
DELISTED
Leaf Group Ltd.
LEAF
-7,276
Closed -$58K

Similar funds

Marshall Wace's Q2 2019 Portfolio in Review

As of Q2 2019, Marshall Wace held 2,123 positions worth $12.2B, up 14% from $10.6B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Marshall Wace deployed $1.17B of net new capital in Q2 2019, opening 434 new positions and adding to 455 existing holdings. Its largest new stake was EPAM Systems: 482,974 shares worth $83.6M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $122M trimmed.

  • Marshall Wace's largest Q2 2019 buy was EPAM Systems: 482,974 shares worth $83.6M.
  • Marshall Wace added most to Boston Scientific in Q2 2019, an estimated $197M increase.
  • Marshall Wace's biggest Q2 2019 reduction was Alphabet (Google) Class A, cutting an estimated $122M.
  • Marshall Wace fully exited iShares MSCI Emerging Markets ETF in Q2 2019, selling an estimated $69.5M.
  • Marshall Wace's ten largest holdings make up 20% of its $12.2B portfolio in Q2 2019.
  • Marshall Wace opened 434 new positions and closed 827 in Q2 2019.
  • Marshall Wace's portfolio value rose 14% quarter-over-quarter to $12.2B.

Based on Marshall Wace's 13F filing for Q2 2019, filed 14 Aug 2019.